214 related articles for article (PubMed ID: 27737744)
1. Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance.
Choudhury RP; Birks JS; Mani V; Biasiolli L; Robson MD; L'Allier PL; Gingras MA; Alie N; McLaughlin MA; Basson CT; Schecter AD; Svensson EC; Zhang Y; Yates D; Tardif JC; Fayad ZA
J Am Coll Cardiol; 2016 Oct; 68(16):1769-1780. PubMed ID: 27737744
[TBL] [Abstract][Full Text] [Related]
2. Effect of anti-IL-1β antibody (canakinumab) on insulin secretion rates in impaired glucose tolerance or type 2 diabetes: results of a randomized, placebo-controlled trial.
Rissanen A; Howard CP; Botha J; Thuren T;
Diabetes Obes Metab; 2012 Dec; 14(12):1088-96. PubMed ID: 22726220
[TBL] [Abstract][Full Text] [Related]
3. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial.
Ridker PM; Howard CP; Walter V; Everett B; Libby P; Hensen J; Thuren T;
Circulation; 2012 Dec; 126(23):2739-48. PubMed ID: 23129601
[TBL] [Abstract][Full Text] [Related]
4. Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized, placebo-controlled trial.
Hensen J; Howard CP; Walter V; Thuren T
Diabetes Metab; 2013 Dec; 39(6):524-31. PubMed ID: 24075453
[TBL] [Abstract][Full Text] [Related]
5. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes.
Everett BM; Donath MY; Pradhan AD; Thuren T; Pais P; Nicolau JC; Glynn RJ; Libby P; Ridker PM
J Am Coll Cardiol; 2018 May; 71(21):2392-2401. PubMed ID: 29544870
[TBL] [Abstract][Full Text] [Related]
6. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Ridker PM; MacFadyen JG; Thuren T; Everett BM; Libby P; Glynn RJ;
Lancet; 2017 Oct; 390(10105):1833-1842. PubMed ID: 28855077
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic characteristics of single-dose Canakinumab in patients with type 2 diabetes mellitus.
Noe A; Howard C; Thuren T; Taylor A; Skerjanec A
Clin Ther; 2014 Nov; 36(11):1625-37. PubMed ID: 25240532
[TBL] [Abstract][Full Text] [Related]
8. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
Ridker PM; Everett BM; Thuren T; MacFadyen JG; Chang WH; Ballantyne C; Fonseca F; Nicolau J; Koenig W; Anker SD; Kastelein JJP; Cornel JH; Pais P; Pella D; Genest J; Cifkova R; Lorenzatti A; Forster T; Kobalava Z; Vida-Simiti L; Flather M; Shimokawa H; Ogawa H; Dellborg M; Rossi PRF; Troquay RPT; Libby P; Glynn RJ;
N Engl J Med; 2017 Sep; 377(12):1119-1131. PubMed ID: 28845751
[TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability of canakinumab, an IL-1β inhibitor, in type 2 diabetes mellitus patients: a pooled analysis of three randomised double-blind studies.
Howard C; Noe A; Skerjanec A; Holzhauer B; Wernsing M; Ligueros-Saylan M; Thuren T
Cardiovasc Diabetol; 2014 May; 13():94. PubMed ID: 24884602
[TBL] [Abstract][Full Text] [Related]
10. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Libby P; MacFadyen JG; Thuren T; Ballantyne C; Fonseca F; Koenig W; Shimokawa H; Everett BM; Glynn RJ
Eur Heart J; 2018 Oct; 39(38):3499-3507. PubMed ID: 30165610
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial.
Everett BM; MacFadyen JG; Thuren T; Libby P; Glynn RJ; Ridker PM
J Am Coll Cardiol; 2020 Oct; 76(14):1660-1670. PubMed ID: 33004131
[TBL] [Abstract][Full Text] [Related]
13. A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease.
Russell KS; Yates DP; Kramer CM; Feller A; Mahling P; Colin L; Clough T; Wang T; LaPerna L; Patel A; Lawall H; Shennak MM; Fulmer J; Nikol S; Smith WB; Müller OJ; Ratchford EV; Basson CT
Vasc Med; 2019 Oct; 24(5):414-421. PubMed ID: 31277561
[TBL] [Abstract][Full Text] [Related]
14. Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial.
Vallurupalli M; MacFadyen JG; Glynn RJ; Thuren T; Libby P; Berliner N; Ridker PM
Ann Intern Med; 2020 Apr; 172(8):523-532. PubMed ID: 32203978
[TBL] [Abstract][Full Text] [Related]
15. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis.
Ruperto N; Brunner HI; Quartier P; Constantin T; Wulffraat N; Horneff G; Brik R; McCann L; Kasapcopur O; Rutkowska-Sak L; Schneider R; Berkun Y; Calvo I; Erguven M; Goffin L; Hofer M; Kallinich T; Oliveira SK; Uziel Y; Viola S; Nistala K; Wouters C; Cimaz R; Ferrandiz MA; Flato B; Gamir ML; Kone-Paut I; Grom A; Magnusson B; Ozen S; Sztajnbok F; Lheritier K; Abrams K; Kim D; Martini A; Lovell DJ; ;
N Engl J Med; 2012 Dec; 367(25):2396-406. PubMed ID: 23252526
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Thuren T; Zalewski A; Libby P
Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
[TBL] [Abstract][Full Text] [Related]
17. Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta.
Mizoguchi M; Tahara N; Tahara A; Nitta Y; Kodama N; Oba T; Mawatari K; Yasukawa H; Kaida H; Ishibashi M; Hayabuchi N; Harada H; Ikeda H; Yamagishi S; Imaizumi T
JACC Cardiovasc Imaging; 2011 Oct; 4(10):1110-8. PubMed ID: 21999871
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study.
Alten R; Gomez-Reino J; Durez P; Beaulieu A; Sebba A; Krammer G; Preiss R; Arulmani U; Widmer A; Gitton X; Kellner H
BMC Musculoskelet Disord; 2011 Jul; 12():153. PubMed ID: 21736751
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial.
Weickert TW; Jacomb I; Lenroot R; Lappin J; Weinberg D; Brooks WS; Brown D; Pellen D; Kindler J; Mohan A; Wakefield D; Lloyd AR; Stanton C; O'Donnell M; Liu D; Galletly C; Shannon Weickert C
Brain Behav Immun; 2024 Jan; 115():191-200. PubMed ID: 37848096
[TBL] [Abstract][Full Text] [Related]
20. Use of canakinumab in the cryopyrin-associated periodic syndrome.
Lachmann HJ; Kone-Paut I; Kuemmerle-Deschner JB; Leslie KS; Hachulla E; Quartier P; Gitton X; Widmer A; Patel N; Hawkins PN;
N Engl J Med; 2009 Jun; 360(23):2416-25. PubMed ID: 19494217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
